Zomedica (ZOM) investor relations material

Executive summary

• Record Q3 revenue was $9.899 million, up 22% YoY; revenue exceeded $9 million for a second consecutive quarter, extending the YoY growth streak to 23 quarters.

• Core commercial revenue, excluding Development Services, grew 18% in Q3 and 14% YTD; Q3 net loss narrowed 48% YoY to $3.166 million.

• Growth reflected therapeutic-device demand, higher diagnostic adoption, Development Services, and disciplined costs and cash management.

Financial highlights

• Q3 revenue was $9.899 million versus $8.1 million, up 22%; 9M revenue was $28.210 million versus $21.6 million, up 31%.

• Q3 operating expenses were $9.5 million, down 21% or $2.5 million YoY; 9M expenses were $30.0 million versus adjusted $37.9 million in 2025, down 21%.

• Q3 net loss was $3.166 million versus $6.1 million; 9M net loss was $11.465 million versus $77.328 million, including $55.833 million of prior-year impairment expense.

• Q3 cash burn improved 32% YoY to $3.2 million; YTD cash burn improved $4.6 million. Adjusted Non-GAAP EBITDA loss was $1.6 million in Q3 versus $3.9 million and $6.3 million for 9M versus $15.6 million.

Outlook and guidance

• Management expects continued consumables growth as the installed base expands and believes the business is positioned to close the year strong; no numerical forward guidance was stated.

• Priorities include executing the growth strategy, improving operating efficiency, and expanding commercial reach; management expects net losses until product revenue offsets operating expenses.

• Existing cash, cash equivalents, and available-for-sale securities are expected to fund operations until cash-flow profitability under the current plan.